- Tous > Medicine Access and Rational Use > Financing
- Tous > Medicine Access and Rational Use > Pricing
- Mots-clés > cost containment policies
- Mots-clés > data collection - pharmaceutical consumption by volume
- Mots-clés > financial and economic crisis
- Mots-clés > global economic crisis
- Mots-clés > medicines policy development
- Mots-clés > pharmaceutical expenditure
- Mots-clés > pharmaceutical market
- Mots-clés > Pharmaceutical Pricing and Reimbursement Information (PPRI)
- Mots-clés > pharmaceutical pricing and reimbursement policies
- Mots-clés > prices / pricing policy
- Mots-clés > dépenses en produits pharmaceutiques
(2014; 15 pages)
Objective: To identify pharmaceutical policy changes during the economic recession in eight European countries and to determine whether policy measures resulted in lower sales of, and less expenditure on, pharmaceuticals.
Methods: Information on pharmaceutical policy changes between 2008 and 2011 in eight European countries was obtained from publications and pharmaceutical policy databases. Data on the volume and value of the quarterly sales of products between 2006 and 2011 in the 10 highest-selling therapeutic classes in each country were obtained from a pharmaceutical market research database. We compared these indicators in economically stable countries; Austria, Estonia and Finland, to those in economically less stable countries, Greece, Ireland, Portugal, Slovakia and Spain.
Findings: Economically stable countries implemented two to seven policy changes each, whereas less stable countries implemented 10 to 22 each. Of the 88 policy changes identified, 33 occurred in 2010 and 40 in 2011. They involved changing out-of-pocket payments for patients in 16 cases, price mark-up schemes in 13 and price cuts in 11. Sales volumes increased moderately in all countries except Greece and Portugal, which experienced slight declines after 2009. Sales values decreased in both groups of countries, but fell more in less stable countries.
Conclusion: Less economically stable countries implemented more pharmaceutical policy changes during the recession than economically stable countries. Unexpectedly, pharmaceutical sales volumes increased in almost all countries, whereas sales values declined, especially in less stable countries.